266 related articles for article (PubMed ID: 20066470)
1. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.
Bergman AM; Adema AD; Balzarini J; Bruheim S; Fichtner I; Noordhuis P; Fodstad O; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
Invest New Drugs; 2011 Jun; 29(3):456-66. PubMed ID: 20066470
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.
Bergman AM; Kuiper CM; Voorn DA; Comijn EM; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
Biochem Pharmacol; 2004 Feb; 67(3):503-11. PubMed ID: 15037202
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts.
Bergman AM; Kuiper CM; Noordhuis P; Smid K; Voorn DA; Comijn EM; Myhren F; Sandvold ML; Hendriks HR; Fodstad O; Breistøl K; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1329-33. PubMed ID: 15571253
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
5. Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells.
Adema AD; Losekoot N; Smid K; Kathmann I; Myhren F; Sandvold ML; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):394-9. PubMed ID: 20544525
[TBL] [Abstract][Full Text] [Related]
6. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
[TBL] [Abstract][Full Text] [Related]
7. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
Bergman AM; Eijk PP; Ruiz van Haperen VW; Smid K; Veerman G; Hubeek I; van den Ijssel P; Ylstra B; Peters GJ
Cancer Res; 2005 Oct; 65(20):9510-6. PubMed ID: 16230416
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.
Pratt SE; Durland-Busbice S; Shepard RL; Donoho GP; Starling JJ; Wickremsinhe ER; Perkins EJ; Dantzig AH
Mol Cancer Ther; 2013 Apr; 12(4):481-90. PubMed ID: 23371859
[TBL] [Abstract][Full Text] [Related]
9. In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate.
Chen P; Chien PY; Khan AR; Sheikh S; Ali SM; Ahmad MU; Ahmad I
Anticancer Drugs; 2006 Jan; 17(1):53-61. PubMed ID: 16317290
[TBL] [Abstract][Full Text] [Related]
10. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
11. The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase.
Eda H; Ura M; F-Ouchi K; Tanaka Y; Miwa M; Ishitsuka H
Cancer Res; 1998 Mar; 58(6):1165-9. PubMed ID: 9515801
[TBL] [Abstract][Full Text] [Related]
12. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
[TBL] [Abstract][Full Text] [Related]
13. Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line.
Kazuno H; Sakamoto K; Fujioka A; Fukushima M; Matsuda A; Sasaki T
Cancer Sci; 2005 May; 96(5):295-302. PubMed ID: 15904471
[TBL] [Abstract][Full Text] [Related]
14. High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 2'-deoxycytidine antimetabolite, 2'-deoxy-2'-methylidenecytidine.
Miwa M; Eda H; Ura M; Ouchi KF; Keith DD; Foley LH; Ishitsuka H
Clin Cancer Res; 1998 Feb; 4(2):493-7. PubMed ID: 9516941
[TBL] [Abstract][Full Text] [Related]
15. Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.
Senanayake TH; Warren G; Wei X; Vinogradov SV
J Control Release; 2013 Apr; 167(2):200-9. PubMed ID: 23385032
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126.
Adema AD; Smid K; Losekoot N; Honeywell RJ; Verheul HM; Myhren F; Sandvold ML; Peters GJ
Invest New Drugs; 2012 Oct; 30(5):1908-16. PubMed ID: 22002019
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
18. Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.
Lam W; Bussom S; Cheng YC
Mol Cancer Ther; 2009 Feb; 8(2):415-23. PubMed ID: 19208827
[TBL] [Abstract][Full Text] [Related]
19. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport.
Song X; Lorenzi PL; Landowski CP; Vig BS; Hilfinger JM; Amidon GL
Mol Pharm; 2005; 2(2):157-67. PubMed ID: 15804190
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H
J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]